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X-linked recessive hypoparathyroidism, due to parathyroid agenesis, has been mapped to a 906-kb region on 
Xq27 that contains 3 genes (ATP11C, U7snRNA, and SOX3), and analyses have not revealed mutations. We 
therefore characterized this region by combined analysis of single nucleotide polymorphisms and sequence-
tagged sites. This identified a 23- to 25-kb deletion, which did not contain genes. However, DNA fiber–FISH 
and pulsed-field gel electrophoresis revealed an approximately 340-kb insertion that replaced the deleted 
fragment. Use of flow-sorted X chromosome–specific libraries and DNA sequence analyses revealed that the 
telomeric and centromeric breakpoints on X were, respectively, approximately 67 kb downstream of SOX3 
and within a repetitive sequence. Use of a monochromosomal somatic cell hybrid panel and metaphase-FISH 
mapping demonstrated that the insertion originated from 2p25 and contained a segment of the SNTG2 gene 
that lacked an open reading frame. However, the deletion-insertion [del(X)(q27.1) inv ins (X;2)(q27.1;p25.3)], 
which represents a novel abnormality causing hypoparathyroidism, could result in a position effect on SOX3 
expression. Indeed, SOX3 expression was demonstrated, by in situ hybridization, in the developing parathy-
roid tissue of mouse embryos between 10.5 and 15.5 days post coitum. Thus, our results indicate a likely new 
role for SOX3 in the embryonic development of the parathyroid glands.
*OUSPEVDUJPO
Hypoparathyroidism (HPT) is an endocrine disorder in which 
hypocalcemia and hyperphosphatemia are the results of a deficien-
cy of parathyroid hormone (PTH) (1). The causes of HPT include 
trauma to the parathyroids during neck surgery, autoimmune 
polyendocrinopathy syndrome type 1, or the complex congential 
abnormalities of the DiGeorge, Kenny-Caffey, and hypoparathy-
roidism, deafness, and renal dysplasia (HDR) syndromes (1, 2). In 
addition, HPT may develop as an isolated endocrinopathy that 
may also be inherited as autosomal dominant (Online Mendelian 
Inheritance in Man [OMIM] 146200), autosomal recessive (OMIM 
146200), or X-linked recessive traits (OMIM 307700) (1, 3–5). 
Some of the autosomal forms of isolated HPT are due to muta-
tions of the PTH gene (1, 3), which is located on chromosome 
11p15, or the calcium-sensing receptor gene (CASR), which is located 
on chromosome 3q21.3 (1, 6). The gene causing the X-linked reces-
sive form, which seems to involve a developmental gene and has 
been mapped to Xq27, remains to be identified (7–9).
X-linked recessive HPT (OMIM 307700) has been reported in 2 
related multigeneration kindreds from Missouri, USA (4, 5, 10). 
Affected subjects, who are males, suffered, if untreated, from neo-
natal or infantile onset of hypocalcemic seizures (4, 5). These indi-
viduals have deficiency of circulating immunoreactive PTH, and an 
autopsy of an affected teenage boy indicated that the HPT was due 
to parathyroid agenesis (11). Clinical immunodeficiency, facial dys-
morphism, deafness, and renal abnormalities, which are notable fea-
tures of some complex congential anomalies (e.g., DiGeorge, HDR, 
and Kenny-Caffey syndromes) (1, 12), are not present in males with 
X-linked recessive HPT (4, 5). Carrier females, who are the mothers 
or grandmothers of affected males, give no history of epilepsy and 
are normocalcemic (4, 5). Linkage studies have mapped X-linked 
recessive HPT to a 906-kb interval (Figure 1) flanked centromerically 
by a polymorphism associated with the diffuse B cell lymphoma (DBL) 
proto-oncogene and telomerically by DXS984 in Xq27.1 (7–9). Fur-
thermore, DNA sequence analyses of the 3 genes, adenosine triphospha-
tase 11C (ATP11C), U7snRNA homologue, and Sry-box 3 (SOX3), that are 
contained within the 906-kb X-linked recessive HPT critical region 
have not revealed any abnormalities (9). These findings together with 
the reported absence of hypocalcemia in a boy with hemophilia B and 
mental retardation who had a chromosomal deletion that encom-
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bacterial artificial chromosome; BLAST, Basic Local Alignment Search Tool; CASR, 
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cial chromosome; PFGE, pulsed-field gel electrophoresis; PH, pleckstrin homology; 
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passed the entire 906-kb interval containing ATP11C, U7snRNA, 
and SOX3 genes (8, 9, 13) suggest that other genomic abnormalities 
such as duplications or translocations, which could cause altered 
gene function (14–19), may underlie the etiology of X-linked reces-
sive HPT. We therefore undertook a detailed characterization of the 
interval containing the X-linked recessive HPT locus.
3FTVMUT
Identification of a deletion-insertion in X-linked recessive HPT. Our initial 
characterization of the X-linked recessive HPT interval began with 
the identification of single nucleotide polymorphisms (SNPs) for 
segregation studies, with a view to reducing the critical region by 
identifying recombinants between the disease and SNP loci. The 
interval between the DBL-associated SNP, rs5907612, and DXS984 
(Figure 1), which is 906 kb in size (9), is contained within a con-
tig formed by 12 bacterial artificial chromosomes (BACs), and a 
search using the GenBank database revealed 2 SNPs (rs732125 
and rs461191) centromeric to the loci for U7snRNA and SOX3. 
The family members of the 2 X-linked recessive HPT kindreds, 
P/60 and W/81 (4, 5), were homozygous and hence uninformative 
for SNP rs461191. However, a deletion involving SNP rs732125 
was detected in the 6 males affected with X-linked recessive HPT, 
and use of 5 sequence-tagged sites (STSs) derived from the DNA 
sequence of BAC RP11-51C14 revealed that this deletion was less 
than or equal to 28 kb in size (Figure 1).
The use of long-range SfiI restriction endonuclease mapping uti-
lizing pulsed-field gel electrophoresis (PFGE) studies (20) with a 
[32P]-labeled SOX3 probe (Figure 2) and long-range PCR (data not 
shown) to confirm this deletion did not reveal the expected loss of 
a DNA fragment up to 28 kb in size. Instead, a gain of a large inser-
tion at the site of the deletion was observed (Figure 2). In order to 
characterize the boundaries of this deletion-insertion and to deter-
mine its DNA sequence, vectorette libraries (20–22) of genomic 
DNA digested with BamHI, EcoRI, HindIII, HpaII, and RsaI were 
constructed for both a normal male (individual IV.14; Figure 2) and 
a male affected with X-linked recessive HPT (individual IV.15). In 
addition, X chromosome–specific EcoRI, RsaI, and TaqI vectorette 
libraries were constructed using flow-sorted chromosomes from a 
male affected with X-linked recessive HPT (individual IV.15; Figure 
2). PCR products were generated utilizing X chromosome–specific 
and vectorette unit binding primers, and amplicons containing the 
breakpoints were identified by use of an oligomer-extension “hot 
blot” assay (23). These targeted PCR products were subcloned into 
pGEM-T and their DNA sequences determined (24). This revealed 
that the telomeric breakpoint had occurred between nucleotides 
38,597 and 38,598 of BAC RP11-51C14 (Figure 1). However, the 
centromeric breakpoint had occurred within a 2 kb (at) dinucleo-
tide-rich repetitive sequence. This rendered it difficult to estab-
lish the exact position of the centromeric breakpoint within this 
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BAC RP11-51C14 (Figure 1). These findings established that the 
deletion was between 23 and 25 kb in size and involved Xq27.1. An 
approximately 1,750-bp BamHI vectorette PCR product encom-
passing the telomeric breakpoint, and adjoining insert DNA was 
sequenced. A Basic Local Alignment Search Tool (BLAST) analysis, 
using the versions available in 2001–2003, of this insert sequence 
obtained from the telomeric breakpoint did not identify any 
matches in the databases. This sequence was used to design insert-
specific primer 1 (ISP1) and ISP2 that would generate insert-spe-
cific PCR products (Figure 3). These were used with DNA from 
a monochromosomal rodent-human somatic cell hybrid panel 
(25), and the insert-specific sequence was shown to originate from 
human chromosome 2 (Figure 3). In addition, a third ISP, ISP3, 
was used in conjunction with X chromosome–specific primer R 
(XSPR) to generate a hybrid PCR product that was specific for the 
HPT telomeric boundary (Figure 3). This revealed the hybrid PCR 
product, which was 321 bp in size (Figure 3), to be present in all 
of the 6 hemizygous males affected with HPT and in all of the 11 
carrier females, who were heterozygous and also had the normal 
237-bp product. The hybrid PCR product was not present in any 
of the 16 unaffected males or 28 unaffected females, all of whom 
had the normal PCR product. Thus, there was cosegregation, with 
a peak log10 of odds (LOD) score of 8.10 at 0% recombination, of 
the deletion-insertion with HPT in the 2 related kindreds.
Characterization of the insertion reveals origin from chromosome 2p25.3. 
The ISPs (ISP1 and ISP2) were utilized to generate a 1,181-bp 
PCR product (Figure 3) that was radiolabeled and used to screen 
chromosome 2–specific P1-derived artificial chromosome (PAC) 
(LL02NP04) and Fosmid (LL02NC03) libraries (26) and the 
Centre d’Études du Polymorphisme Humain (CEPH) megaYAC 
library (27). This yielded 1 positive fosmid clone, AG63A8, and 1 
nonchimeric yeast artificial chromosome (YAC) clone, 972C12. 
Combined use of the fosmid clone, from chromosome 2, with BAC 
RP11-51C14, from Xq27, in dual-color FISH analyses (28) of meta-
phase spreads, confirmed the presence of the insertion at Xq27.1 
and revealed that it originated from chromosome 2p25 (Figure 4). 
Thus, in normal males hybridization with fosmid AG63A8 yielded 
signals from chromosome 2pter only; whereas, in males affected 
with X-linked recessive HPT and in female carriers, fosmid AG63A8 
hybridization signals were observed from chromosome 2pter and 
Xqter. Furthermore, the merging of the green signal, from fos-
mid AG63A8, with the red signal, from BAC RP11-51C14, on the 
X chromosome harboring the deletion-insertion to yield a yellow 
signal and the use of DNA fibre-FISH analysis (28) revealed that 
the 2p25 insertion was adjacent to the BAC RP11-51C14 sequence 
(Figure 4). Thus, a contiguous signal was obtained from the 2 X chro-
mosome BACs RP11-359I11 and RP11-51C14 in the normal male, 
consistent with their juxtaposed locations (Figures 1 and 4). How-
ever, such a contiguous signal was not observed in the male affect-
ed with X-linked recessive HPT, whereas use of the chromosome 
2p25–derived YAC 972C12 yielded a contiguous signal (Figure 4). 
These findings, which indicate the insertion of chromosome 2p25 
sequence within that of Xq27.1 sequence, are consistent with the 
presence of a deletion-insertion in the male affected with X-linked 
recessive HPT. This event is likely to have arisen in the founder, 
more than 6 generations ago (4, 5), by nonhomologous recombi-
nation that probably involved the (at) dinucleotide-rich repetitive 
sequence at the centromeric breakpoint of the deletion on Xq27.1 
(Figure 3). The precise nature of any other associated chromosomal 
abnormalities, such as deletions of 2p25, in the founder cannot be 
determined. However, it is important to note that males affected 
with X-linked recessive HPT and carrier females have normal cop-
ies of chromosome 2 (Figure 4). Thus, the occurrence of X-linked 
recessive HPT in the progeny of the founder is due to inheritance 
of the abnormal X chromosome that harbors the deletion-insertion 
involving chromosomes Xq27.1 and 2p25.
The extent of the chromosome 2p25 insert was further charac-
terized by first determining the end sequences (20) of YAC 972C12 
and then identifying BACs that contained these sequences, with 
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RP11-455F15 and RP13-542C4 contained DNA sequences that 
matched the left- and right-arm end sequences of YAC 972C12, 
respectively, and the sequences of these BACs were in turn 
used to identify 6 other BACs (i.e., RP13-539J13, RP11-97B21, 
CTD2029L3, RP11-1268F2, RP13-932E12, and RP11-1294H20) 
and 1 fosmid (XXfos-83269E11) to assemble a contig. The size of 
the insert sequence was estimated to be less than or equal to 500 kb 
by DNA fiber–FISH analysis (28) that utilized the chromosome 
Xq27 BACs RP11-359I11 and RP11-51C14 and the chromosome 
2p25–derived YAC 972C12 (Figure 4). These results also revealed 
that the entire 2p25 insert was contained within the 750-kb sequence 
of YAC 972C12. The use of DNA from these clones and ISPs (ISP1 
and ISP2; Figure 3) for the telomeric boundary in PCRs estab-
lished that this breakpoint was on BAC CTD-2029L3, and the use 
of metaphase-FISH analysis (28) confirmed this and revealed that 
the entire 176-kb sequence of RP11-1268F2 was contained within 
the insert and that RP13-542C4 harbored the centromeric bound-
ary (Figure 4). These results also revealed that the chromosome 
2p25 sequence was inverted upon insertion at Xq27.1 (Figure 5). 
DNA sequence analysis of the chromosome 2p25 clones and the 
insert revealed that the 2p telomeric breakpoint of the insert was 
between nucleotides 94,427 and 94,428 of BAC CTD-2029L3 and 
that the centromeric breakpoint was located between nucleotides 
40,000 and 75,000 of BAC RP13-542C4, thereby indicating that 
the size of the insert was 305–340 kb and from 2p25.3. Thus, 
X-linked recessive HPT is caused by a molecular deletion-inser-
tion [del(X)(q27.1) inv ins (X;2)(q27.1;p25.3)] involving a loss of 
23–25 kb from Xq27.1 and an inverted insertion of 305–340 kb 
from 2p25.3 to Xq27.1. A search for such a deletion-insertion and 
other deletions or insertions in 9 unrelated males with idiopathic 
HPT using PCR primers for the 2 SNPs (rs732125 and rs461191; 
Figure 1), the 5 STSs (a–e; Figure 1), and the telomeric breakpoint 
of X-linked recessive HPT (ISP3 and XSPR; Figure 3) did not reveal 
any abnormalities, thereby indicating that the deletion-insertion 
del(X)(q27.1) inv ins (X;2)(q27.1;p25.3) is likely to be a rare event 
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Search for expressed sequences within the deletion-insertion. In order 
to elucidate further the genetic consequences of this complex 
chromosomal rearrangement associated with X-linked recessive 
HPT, we investigated the involved DNA sequences for expressed 
genes. The 2p25.3 inserted 305–340 kb sequence contained a 
large segment of the syntrophin gamma 2 (SNTG2; NM_018968) 
gene, that consists of the 3′ part of intron 1 together with exons 
2 to 16 and the 5′ part of intron 16. Thus, this inserted seg-
ment of the SNTG2 gene did not contain the normally utilized 
start and stop codons, which are in exons 1 and 17, respectively 
(29). However, SNTG2 has been reported to have alternative tran-
scripts (29), and our analysis of the DNA sequences indicated 
that there may be alternative exons within the 2p25.3 insert-
ed approximately 61 kb of intron 1 and the adjacent Xq27.1 
sequence (Figure 5). The usage of these was investigated by uti-
lizing EBV-transformed lymphoblastoid RNA from males affect-
ed with X-linked recessive HPT and normal males for RT-PCR 
analysis (3). These analyses in both the affected and normal 
individuals revealed that 2 upstream exons were spliced to the 
invariant exon 2 of SNTG2, but DNA sequence analysis revealed 
that the resultant transcripts did not have open reading frames 
(data not shown) and that they were therefore not likely to be of 
functional significance. These results were confirmed by analyz-
ing alternative SNTG2 transcripts that were obtained by use of 
5′ rapid amplification of cDNA ends (RACE) and human kidney 
Marathon-Ready cDNA (BD Biosciences) (30) (data not shown). 
The 23- to 25-kb sequence deleted from Xq27.1 deleted 23–25 kb 
sequence is not known to contain any genes or ESTs, but nucleic 
acid identification X (NIX) analysis indicated the presence of 4 
putative exons. Oligonucleotide primers specific for these were 
designed and utilized in RT-PCR analysis that used 35 cycles to 
facilitate detection of low levels of illegitimate transcripts (3) in 
RNA from EBV-transformed lymphoblastoids of a normal male, 
as normal human adult or embryonic parathyroid tissue was 
not available. The RT-PCR analysis failed to detect transcripts, 
thereby indicating that this 23- to 25-kb sequence deleted from 
Xq27.1 is likely to be a noncoding region, although it is impor-
tant to note that illegitimate transcripts of developmental genes 
may occasionally not be detected in RNA from EBV-transformed 
lymphoblastoids (3, 17).
Sox3 expression in developing parathyroids. The noncoding region 
encompassed by the 23- to 25-kb deleted sequence is situated 67 
kb downstream of SOX3, and this location suggested the possi-
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genomic elements such as enhancers, repressors, or insulators 
that may be involved in transcription regulation have been 
reported to be located up to 1 Mb upstream or downstream of 
the transcriptional unit (14). As a first step in exploring such a 
possibility, we examined for Sox3 expression by in situ hybrid-
ization (Figure 6) in the pharyngeal pouches and developing 
parathyroids of mouse embryos, as such human tissues are not 
available. We also assessed for Casr expression, which has been 
reported to be particularly expressed in parathyroid and thyroid 
C cells that produce calcitonin (6), as a control. These studies 
revealed Casr expression, as early as 10.5 days post coitum (dpc), 
in the parathyroid precursor tissue at the endodermal margin of 
the third pharyngeal pouch (Figure 6). At this stage, on serial sec-
tions, Sox3 expression was detected in an adjacent but nonover-
lapping domain, in the posterior margin of the third, and also 
second, pharyngeal pouch. Sox3 expression was also observed at 
13.5 and 15.5 dpc, in the developing parathyroids and thymic 
and thyroid rudiments, but this was dramatically reduced by 
18.5 dpc. In contrast, Casr was strongly and uniformly expressed, 
at 18.5 dpc, in the parathyroids, while in the thyroid its expres-
sion was clustered in foci that may likely represent C cells (6). 
Thus, Sox3 is expressed between 10.5 and 15.5 dpc in the second 
and third pharyngeal pouches and the developing parathyroids. 
These findings are consistent with the hypothesis that SOX3 
misexpression may lead to abnormalities of parathyroid devel-
opment. Such misexpression of SOX3 could be caused by a posi-
tion effect resulting from the deletion-insertion [del(X)(q27.1) 
inv ins (X;2)(q27.1;p25.3)], which is situated 67 kb downstream 
of SOX3 and is associated with X-linked recessive HPT.
%JTDVTTJPO
Our studies have identified a novel molecular deletion-inser-
tion involving chromosomes Xq27.1 and 2p25.3 in patients with 
X-linked recessive HPT due to parathyroid agenesis (11). Deletion-
insertions and translocations are well documented in the etiology 
of cancers, e.g., thyroid carcinomas and leukemias (31, 32), and 
in nonfamilial forms of diseases such as DiGeorge and HDR syn-
dromes (1, 2, 12). However, to our knowledge, this is the first report 
of a stably inherited germline X-autosomal rearrangement that 
causes disease. This deletion-insertion is likely to have arisen, in 
the founder, by nonhomologous recombination, and the (at) dinu-
cleotide-rich repetitive sequence associated with the centromeric 
breakpoint is consistent with this postulated mechanism (33). This 
event appears to be an extraordinarily rare one that likely occurred 
once and more than a century ago in North America, as only 2 
related kindreds with X-linked recessive HPT have been reported, 
and both are from Missouri (4, 5, 10). Moreover, our identification 
of this deletion-insertion highlights the important role for genetic 
abnormalities that involve noncoding regions in causing disease, 
a feature that is likely to be of significance in the search for the 
molecular basis of other Mendelian inherited diseases for which 
coding region abnormalities have not been identified (14).
The manner in which this deletion-insertion [del(X)(q27.1) inv 
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coding Xq27.1 sequence and an inverted insertion of 305–340 kb 
from chromosome 2p25.3 to Xq27.1 in the founder (Figure 5), 
affects the embryonic development of the parathyroids from 
the third and fourth pharyngeal pouches in humans remains to 
be elucidated. At least 4 possible explanations could be consid-
ered. First is the possibility that trisomy of the inserted 2p25.3 
sequence may result in a dosage effect that alters parathyroid 
development. However, this seems unlikely, as patients with 2p 
trisomy have not been reported to suffer from hypocalcemia or 
HPT (34). Moreover, such 2p25.3 trisomy occurs in the X-linked 
recessive HPT carrier females, who are normocalcemic and do 
not have HPT (4, 5). Thus, increased dosage of 2p25.3 is not the 
cause of X-linked recessive HPT.
Second is the possibility that expression of abnormal splice 
variants of SNTG2 may disrupt parathyroid development. SNTG2 
belongs to the family of SYNTROPHIN proteins, which contain 
at least one pleckstrin homology (PH) domain, a PSD-95, discs-
large, Z0-1 (PDZ) domain, and a C-terminal syntrophin unique 
(SU) region (35). All of the syntrophin proteins associate with 
dystrophin and dystrobrevin through an interaction between 
the SU and adjacent PH domain (29, 36), while the PDZ domain 
interacts with receptors, ion channels, and other signaling pro-
teins (37–39). Thus, an SNTG2 isoform may regulate parathyroid 
development by its action as an adaptor protein that either links 
transmembrane receptors to intracellular signaling cascades or 
facilitates recycling of G protein–coupled receptors in the process 
of receptor resensitization. This possibility, although attractive, 
is unlikely, as the SNTG2 transcripts that result from the inser-
tion, which contains approximately 61 kb of intron 1 together 
with exons 2–16 (Figure 5), do not have open reading frames and 
hence lack the critical PDZ, SU, and PH domains.
Third is the possibility that the 23–25 kb deleted Xq27.1 
sequence contains an unidentified gene whose loss disrupts para-
thyroid development. However, this is unlikely, as the 23–25 kb 
DNA sequence is not reported to contain genes or ESTs, and our 
studies using EBV-transformed lymphoblastoid RNA failed to 
detect any transcripts. Furthermore, a patient who has a deletion 
spanning the approximately 1-Mb interval from FACTOR 9 (F9) to 
DXS984 (Figure 1) has been reported to suffer from hemophilia B 
and mental retardation but not hypocalcemia or HPT (13). Thus, 
it seems likely that this 23–25 kb deleted region is noncoding.
Fourth is the possibility that this noncoding region could con-
tain regulatory regions for SOX3, which is located 67 kb telomer-
ic to the deletion-insertion. Thus, a disruption of such putative 
regulatory sequences that may alter SOX3 expression would be 
postulated to lead to parathyroid agenesis and X-linked recessive 
HPT. Our demonstration that Sox3 is expressed in the third pha-
ryngeal pouch and developing parathyroids of mouse embryos 
between 10.5 and 15.5 dpc (Figure 6) provides support for such 
a role of SOX3 in parathyroid genesis. SOX3 has not previously 
been shown to be expressed in the parathyroids, and thus our 
results add to the growing list of transcription factors, which 
include GCMB, GATA3, TBX1, HOXA3, PAX1, and PAX9, that 
operate in parathyroid development (1, 12, 24, 40). Sox3 is also 
expressed in the infundibulum of the developing pituitary and 
presumptive hypothalamus of mouse embryos, with its expres-
sion in the latter being maintained in the adult (15, 41). More-
over, SOX3 abnormalities are associated with X-linked hypopitu-
itarism and with X-linked mental retardation that occurs with 
growth hormone deficiency (15, 17, 18).
SOX3 belongs to a family of genes encoding high-mobility group 
box transcription factors and is related to SRY, the sex-determin-
ing gene on the Y chromosome. The mouse homolog is expressed 
in the prestreak embryo and subsequently in the developing 
CNS that includes the region of the ventral diencephalon, which 
induces development of the anterior pituitary and gives rise to 
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roids (Figure 6). Patients with X-linked hypopituitarism have 
been reported to have duplications involving a 686-kb to 13-Mb 
region that contains SOX3 (15–17), and overexpression of SOX3 
has been reported to inhibit Wnt signaling, which has an impor-
tant role in pituitary development (43). Furthermore, increased 
levels of SOX3 have been shown to cause developmental hypopla-
sia of tissues, such as the lens and otic placodes in fish embryos 
(44). Reduced levels of SOX3 expression also result in hypopituita-
rism. Thus, SOX3-null mice have abnormal pituitary development 
associated with hypopituitarism, craniofacial abnormalities, and 
midline CNS defects (41). These phenotypic features are similar 
to those observed in patients with X-linked hypopituitarism and 
with X-linked mental retardation and growth hormone deficiency 
who have in-frame duplications of 21 bp or 33 bp encoding for 
7 or 11 alanines, respectively, in a polyalanine tract of the SOX3 
gene (17, 18). The polyalanine tract expansion resulted in a reduc-
tion in SOX3 transcriptional activity that was associated with an 
impaired nuclear localization of the mutant protein (17). These 
findings demonstrate that pituitary development is sensitive to 
SOX3 dosage, and that both loss- and gain-of-function mutations 
can result in X-linked hypopituitarism (15, 16, 18, 41, 45).
Patients with X-linked hypopituitarism have not been reported 
to suffer from HPT (15–18), and, conversely, the patients affected 
with X-linked recessive HPT do not suffer from hypopituitarism 
(4, 5, 8). These clinical differences may be due to the differences 
in the temporal expression patterns of SOX3 in the pituitary 
and parathyroids or to interactions with different tissue-spe-
cific enhancers or repressors. Alternatively, they may be due to 
differences in the locations of the associated SOX3 genomic 
abnormalities, and it is important to note that X-linked hypo-
pituitarism is associated with either duplications of the entire 
SOX3 coding region or with an intragenic expansion of a poly-
alanine tract (15–18), whereas X-linked recessive HPT is associ-
ated with a deletion that is approximately 67 kb downstream 
from the SOX3 coding region (Figure 5). This situation may be 
analogous to that reported to occur in disorders associated with 
abnormalities of the gene encoding sonic hedgehog (SHH) (14). 
SHH is a secreted protein that provides key inductive signals 
for the patterning of ventral neural tube, the anterior posterior 
limb axis, and the ventral somites (14). SHH gene abnormali-
ties lead to holoprosencephaly type 3 (HPE3) and preaxial poly-
dactyly (PPD) in humans (14). HPE3 is caused by deletions or 
point mutations that involve the coding region and result in 
haploinsufficiency of SHH, while PPD is caused by breakpoints 
or point mutations within a limb regulatory element that is 1 
Mb upstream of SHH (14). These findings illustrate that phe-
notypes caused by mutations in regulatory elements can be very 
different from those caused by mutations of coding regions 
and that point mutations in regulatory elements at a distance 
as far as 1 Mb from the gene promoter can have a detrimen-
tal affect on embryonic development (14). Thus, it seems likely 
that the differences between X-linked recessive HPT and hypo-
pituitarism occur because the HPT deletion-insertion, which is 
approximately 67 kb downstream of SOX3, involves disruption 
of regulatory elements, whereas the abnormalities resulting in 
hypopituitarism involve alterations of the SOX3 coding region. 
It is also important to note that the disruption in the regulatory 
region could also lead to upregulation or misregulation of the 
gene, thereby resulting in phenotypes due to gain-of-function 
(i.e., hypermorphic or neomorphic).
The location of the deletion-insertion approximately 67 kb 
downstream of SOX3 in X-linked recessive HPT patients is likely 
to result in altered SOX3 expression, as SOX3 expression has been 
reported to be sensitive to position effects caused by X chromo-
some abnormalities (14, 19). Indeed, reporter-construct studies 
of the mouse Sox3 gene have demonstrated the presence of both 
5′ and 3′ regulatory elements (46), and thus it is possible that 
the deletion-insertion in the X-linked recessive HPT patients 
may have a position effect on SOX3 expression and parathyroid 
development from the pharyngeal pouches. Indeed such posi-
tion effects on SOX genes, which may be exerted over large dis-
tances, have been reported. For example, the very closely related 
Sox2 gene has been shown to have regulatory regions spread 
over a long distance, both 5′ and 3′ to the coding region (47), 
and disruption of sequences at some distance 3′ (>20 kb) have 
recently been reported to lead to loss of expression in the devel-
oping inner ear and absence of sensory cells, whereas expression 
in other sites is unaffected (48). Similarly for the SRY gene, which 
probably originated from SOX3 (13), both 5′ and 3′ deletions 
result in abnormalities of sexual development (14, 19, 49), and 
translocation breakpoints more than 1 Mb upstream of the SOX9 
gene have been reported to result in Campomelic dysplasia due 
to removal of elements that regulate SOX9 expression (14, 19). 
Thus, our studies, which have identified a molecular deletion-
insertion that may cause a position effect on SOX3 expression 
leading to X-linked recessive HPT, point to a potential role for 
the SOX3 gene in the embryological development of the parathy-
roid glands from the pharyngeal pouches.
.FUIPET
Families. Two related kindreds from Missouri, USA, in whom idiopathic 
HPT had been inherited in an X-linked recessive manner in 5 or more gen-
erations (4, 5) and in whom linkage between the disease and polymorphic 
loci from chromosome Xq26–27 (Figure 1) had been established (7–9), were 
investigated. Venous blood was collected, with approved Human Studies 
Committee (Washington University School of Medicine) guidelines used 
to obtain informed consent, from 61 family members (6 affected males, 11 
carrier females and 44 unaffected [16 males, 28 females]) and 9 unrelated 
males with idiopathic HPT, as previously reported (7, 8).
Analysis of DNA and RNA. DNA was prepared from peripheral blood 
leukocytes or from EBV-transformed lymphoblastoids, and RNA 
was prepared from EBV-transformed lymphoblastoids, as previously 
described (3). Oligonucleotide primers were designed for use in PCR 
amplification of DNA sequences, as previously reported (3, 9, 20) to: 
detect SNPs; characterize the boundaries of deletions (ISP3 5′-GGGC-
TAACGAGAACGCAGAGGC-3′; XSPF 5′-GCTAGTAATGTTCTCT-
GTCTTGAATTTGCCC-3′ ; XSPR 5′-GGATCCTCATATCCCACT-
GTGGTCAAAGG-3′) and insertions by use of STSs (STS a forward 
(F) 5′-AGGTGGCAATTTCAAGAGTGC-3′, reverse (R) 5′-CCGTGT-
GAAGCCTATGACTGC-3′; STS b F 5′-GCAACTAAAGAAGGGCT-
TAGAGG-3′, R 5′-CACAATACTTCTGGAGGCAAGG-3′; STS c F 5′-CCTA-
ACTTTGCCCCTTCACTGC-3′, R 5′-TGGAGGAAGAAAACTTTGAGC-3′; 
STS d F 5′-TGCCTCAGTCTCCTCACTTGGC-3′, R 5′-CTCATATCCTGC-
CACCAAATTCC-3′; STS e F 5′-TGGCTCACACCTGTAAATACC-3′, R 5′-
GCAACATCGGTGGGAACAGCAG-3′); generate probes for screening of 
YAC, PAC, and Fosmid libraries; determine the chromosomal locations 
of novel genomic sequences by use of a rodent-human monochromo-
somal somatic cell hybrid panel (ISP1 5′-CCCATTTAAGTATAAAACT-
TATGTTCCTCC-3′; ISP2 5′-CGTGAATCCCTGCATTCCCGTGAGG-3′); 
and identify cDNAs using 5′ RACE (30). Oligonucleotide primers were 
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also used with RNA in RT-PCR that utilized avian myeloblastosis virus 
reverse transcriptase (Life Sciences Inc.) to identify transcripts, as previ-
ously described (3, 9). The DNA sequences of PCR products were deter-
mined using Taq polymerase cycle sequencing and a semi-automated 
laser detection system (Sequencer 373A; Applied Biosystems), as previ-
ously reported (9). High-molecular-weight DNA was used for restriction 
mapping using 4-fold excess of the “rare cutter” endonuclease SfiI and 
the resulting fragments separated by PFGE; transferred by the method of 
Southern to Hybond-N+ (Amersham Biosciences UK Ltd.) membranes, 
which were hybridized using a [32P]-labeled DNA probe for SOX3 (F 5′-
TCCGAGCAGGTATATAAGGGG-3′; R 5′-TTCGCACTACTCTTGCCT-
GC-3′); and visualized by autoradiography (20).
Isolation, preparation, and analysis of YAC, BAC, PAC, and Fosmid clones. 
BAC clones were identified using BLAST and the NCBI GenBank data-
base. YAC clones were identified from the CEPH megaYAC library (27), 
and PAC and Fosmid clones were identified from the human chromo-
some 2–specific filter libraries LL02NP04 and LL02NC03 (26), respec-
tively, using [32P]-labeled DNA probes. These DNA probes were generated 
from PCR products using the Megaprime DNA labeling system, accord-
ing to the manufacturer’s recommendations (Amersham Biosciences UK 
Ltd.). The DNA sequences of the YAC, PAC, and Fosmid clones were not 
available, and the terminal portions of these clones were isolated using 
ligation-mediated end rescue methods such as inverse or vectorette PCR 
(20, 22, 50) and the DNA sequences of the products determined. A contig 
consisting of these clones was assembled, as described previously (20). 
These clones were prepared and labeled by incorporation of labeled dUTP 
for use on metaphase spreads and FISH.
Metaphase- and DNA fiber–FISH. Metaphase chromosome spreads were 
prepared from EBV-transformed lymphoblastoid cells (3) following 
standard procedures, and single- and dual-color FISH was performed, as 
previously described (28), using biotin- and digoxigenin-labeled probes. 
Biotinylated probes were detected with Texas red–conjugated streptavidin 
(Invitrogen Corp.), and digoxigenin labeled probes were detected with a 
mouse anti-digoxigenin antibody (Roche Diagnostics Corp.) and goat 
anti-mouse Alexa-488 (Invitrogen Corp.). The slides were mounted with 
VECTASHIELD (Vector Laboratories) containing DAPI for chromosome 
counterstaining. A minimum of 25 metaphases were analyzed for each 
hybridization experiment using an Olympus BX-51 epifluorescence micro-
scope coupled to a SenSys charge-coupled device camera (Photometrics; 
Roper Scientific Inc.). Texas red, Alexa-488, and DAPI fluorescence images 
were taken as separate gray-scale images using specific filter combinations 
and then pseudocolored and merged using the software package Genus 
version 2.81 (Applied Imaging International). DNA fiber slides were pre-
pared as described previously (28) and triple-color FISH performed using 
biotin-, digoxigenin-, and Alexa-594–labeled probes. Biotinylated probes 
were visualized using fluorescein-conjugated streptavidin, and digoxigen-
in-labeled probes were visualized using mouse anti-digoxigenin (Roche 
Diagnostics Corp.) followed by a layer of rabbit anti-mouse Cy5 (Stratech 
Scientific Ltd.) and a final layer of goat anti-rabbit Cy5 (Stratech Scien-
tific Ltd.). Probes labeled with Alexa-594 dUTP (Invitrogen Corp.) were 
visualized directly. The slides were mounted with VECTASHIELD (Vector 
Laboratories), and images were captured and analyzed using a Bio-Rad 
MRC1024 confocal microscope (Bio-Rad Laboratories).
Genomic library construction. Leukocyte DNA from a male affected with 
X-linked recessive HPT (individual IV.15 from family W/81; Figure 2) 
and an unaffected (control) male (individual IV.14 from family W/81; 
Figure 2) was digested with BamHI, EcoRI, HindIII, HpaII, and RsaI and 
used to construct genomic libraries utilizing the Vectorette II system 
(Sigma-Aldrich) (22). In order to enrich the source of the HPT insert 
abnormality, flow-sorted X chromosomes extracted from EBV-trans-
formed lymphoblastoids (51) of a male affected with X-linked reces-
sive HPT (individual IV.15 from family W/81; Figure 2) were utilized 
to generate EcoRI, RsaI, and TaqI vectorette libraries, using previously 
reported methods (22, 51). These libraries were employed as template 
DNA for PCR amplification using XSPs in conjunction with a Vector-
ette unit binding primer (Sigma-Aldrich). Targeted PCR products were 
identified using an oligomer-extension “hot blot” assay, as previously 
described (23). Targeted products were then excised from a duplicate gel, 
the DNA extracted, and their sequence determined using Taq polymerase 
cycle sequencing (9, 12, 24).
Detection of Sox3 and Casr expression in mouse embryos by in situ hybridiza-
tion. Parkes mice were staged according to the date of the vaginal plug. 
Embryos were harvested, fixed overnight in 4% paraformaldehyde at 4°C, 
cryoprotected in 20% sucrose, and embedded in OCT (BDH), using previ-
ously described methods (41). In situ hybridizations using cryosections 
were performed as described previously (52) using Sox3 (41) and Casr ribo-
probes. The Casr riboprobe, which was 979 bp in size, was generated by 
RT-PCR using total RNA from mouse (129/Ola) embryonic stem cells 
together with primers specific to exon 2 (5′-AGACCAGAGTCTGTG-
GAGTGC-3′, nucleotides 685–705; NM_013803 Mus musculus Calcium-
sensing receptor [Casr], mRNA) and exon 4 (5′-CCTTCCTCGTGACTTCT-
CACG-3′, nucleotides 1,663–1,643). The RT-PCR product was subcloned 
into pGEM-T, the construct linearized using NdeI, and an antisense 
digoxigenin-labeled Casr probe generated using T7 RNA polymerase. All 
experiments on mice were performed using protocols approved under the 
United Kingdom Animal (Scientific Procedures) Act. All animal proce-
dures were authorized by the United Kingdom Home Office.
Database searches. Nucleotide sequence analyses and comparisons were 
performed using the GenBank/BLAST (http://www.ncbi.nlm.nih.gov/
BLAST/), Ensembl/BLAST (http://www.ensembl.org), and NIX (no lon-
ger available) databases and programs available in 2001–2004. OMIM was 
accessed on the World Wide Web (http://www.ncbi.nlm.nih.gov/omim/).
Linkage analysis. Data from the present and previously reported stud-
ies (7, 8) of the 2 related kindreds, families P/60 (4) and W/81 (5), were 
pooled for linkage studies. Conventional 2-point LOD scores were calcu-
lated using a web-based linkage computer application, GLUE (LITBIO; 
http://www.litbio.org).
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